Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases.

Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. Circulation (2016) 1.48

Detection and Characterization of the Effect of AB-FUBINACA and Its Metabolites in a Rat Model. J Cell Biochem (2015) 0.76

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35

Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA (2001) 17.91

Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ (2009) 17.73

Probability of stroke: a risk profile from the Framingham Study. Stroke (1991) 10.14

Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06

Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64

Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke (1994) 5.83

A compendium of gene expression in normal human tissues. Physiol Genomics (2001) 5.66

Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26

Computational Proteomics Analysis System (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res (2006) 4.32

Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91

The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) (2006) 3.03

Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation (2007) 2.72

Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation (2006) 2.40

Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol (2010) 2.34

The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev (2005) 2.19

Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J Proteome Res (2006) 2.10

Prediction of ischemic stroke risk in the Atherosclerosis Risk in Communities Study. Am J Epidemiol (2004) 1.94

The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab (2004) 1.70

Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials. PLoS Clin Trials (2007) 1.54

Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J (1982) 1.53

Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Arch Intern Med (2008) 1.34

Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab (2005) 1.31

Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med (2004) 1.21

Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med (2009) 1.21

Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med (2008) 1.19

Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke (2009) 1.19

Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int (2012) 1.16

Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab (2006) 1.15

Heme-hemopexin complex attenuates neuronal cell death and stroke damage. J Cereb Blood Flow Metab (2009) 1.09

Postmenopausal estrogen and progestin effects on the serum proteome. Genome Med (2009) 1.07

Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells. J Biol Chem (2005) 1.01

Beta 2 microglobulin and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke (2011) 0.98

Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling. Genome Med (2010) 0.92

Relationship of beta2-microglobulin to arterial stiffness in Japanese subjects. Hypertens Res (2005) 0.88

Serum amyloid A protein levels in haemodialysis patients. Nephrol Dial Transplant (1996) 0.79